Abstract 3075
Background
Patients are living longer with recurrent breast cancer, yet there is a lack of survivorship programs for these individuals. They face unique challenges due to the lack of curative treatments and limited supportive care resources. Challenges include fluctuations in functional status, changes in relationships, communication with loved ones, and existential concerns. Health related quality of life has been found to be different, further widening the gap in care.
Methods
Survivors were referred for a one-hour coaching intervention tailored to their needs based upon results of their Functional Assessment of Cancer Therapy-Breast (FACT-B) survey. Patient satisfaction was assessed immediately after and at two weeks post the intervention. A paired t-test was used to evaluate quality of life sores before and two weeks following participation in the survivorship session.
Results
Statistically significant (p=.000) improvements were observed overall and in each subscale of the FACT-B survey. Patient satisfaction was high immediately post the intervention and remained high at the two-week assessment.
Conclusions
This project successfully demonstrated that an individual coaching intervention can be implemented to improve the quality of life in patients with recurrent breast cancer. The key findings support that integration of a survivorship program is associated with high patient satisfaction and increased quality of life. As chronic breast cancer survivors encompass a broad and heterogeneous population, survivorship programs should be developed that address the needs of this unique patient population. Creation of an infrastructure that promotes individualized care to survivors with recurrent breast cancer is an essential component of providing holistic care across the cancer continuum. Oncology nurse navigators have a unique relationship with their patients and implementing this program provides an opportunity to address these important and clinically relevant unmet needs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Graduate scholarship in Cancer Nursing Practice GSCNP-18-07501 from the American Cancer Society and a Clinical Doctoral Scholarship from the Oncology Nursing Foundation Endowment.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2262 - Real world experience of Nivolumab therapy in Metastatic Renal Cancer patients: a 3 year multi-centre review
Presenter: Joanna Hack
Session: Poster Display session 3
Resources:
Abstract
4441 - “A pilot study of tremelimumab (treme) with or without cryoablation (cryo) in patients (pts) in metastatic renal cell carcinoma (mRCC).”
Presenter: Matthew Campbell
Session: Poster Display session 3
Resources:
Abstract
2613 - Lenvatinib (Len) alone or in combination with Everolimus (Eve) in heavily pretreated patients (pts) with metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitors (ICI) and VEGFR-targeted therapies: A single-institution experience
Presenter: Andrew Wiele
Session: Poster Display session 3
Resources:
Abstract
3249 - Weight loss is an underestimated adverse event with cabozantinib in patients with metastastic renal cell carcinoma (mRCC).
Presenter: Emeline Colomba
Session: Poster Display session 3
Resources:
Abstract
2405 - Impact of corticosteroids on nivolumab activity in metastatic clear cell renal cell carcinoma.
Presenter: Felix Lefort
Session: Poster Display session 3
Resources:
Abstract
4020 - Skeletal muscle loss as an adverse event during Cabozantinib treatment in patients with metastatic renal cell carcinoma
Presenter: Carolina Alves Costa Silva
Session: Poster Display session 3
Resources:
Abstract
2407 - Long term relative survival (RS) in patients with primary metastatic kidney cancer (primary mRCC): an analysis of 2,167 patients from the Austrian National Cancer Registry (ANCR).
Presenter: Monika Hackl
Session: Poster Display session 3
Resources:
Abstract
2470 - Advanced renal cell carcinoma: first results from the prospective research platform CARAT for patients with mRCC in Germany
Presenter: Peter Goebell
Session: Poster Display session 3
Resources:
Abstract
1533 - Are immune checkpoint inhibitors a valid option for papillary Renal Cell Carcinoma? Transcriptomic characterization of the immune infiltrate
Presenter: Manon De Vries-brilland
Session: Poster Display session 3
Resources:
Abstract
3367 - Treatment-Free Survival, With and Without Toxicity, as a Novel Outcome Applied to Immuno-Oncology Agents in Advanced Renal Cell Carcinoma
Presenter: Meredith Regan
Session: Poster Display session 3
Resources:
Abstract